Press releases
- Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
- Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
- Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
Key statistics
As of last trade Surmodics Inc (SU6:FRA) traded at 37.60, -2.08% below its 52-week high of 38.40, set on Jun 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.60 |
---|---|
High | 37.60 |
Low | 37.60 |
Bid | 38.20 |
Offer | 39.80 |
Previous close | 37.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 14.26m |
Free float | 13.73m |
P/E (TTM) | 43.56 |
Market cap | 596.13m USD |
EPS (TTM) | 0.9597 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 07:02 BST.
More ▼